GP KFPs / SAQs · metabolic-and-endocrine-health
Obesity and weight management — KFP-style written assessment
KFP-style staged scenarios on obesity and weight management: applying DPP evidence to a prediabetes consultation, choosing pharmacotherapy by patient profile, bariatric surgery referral criteria, and the Biggest Loser biology of weight regain.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Obesity: chronic disease, not willpower failure — DPP lifestyle, GLP-1 pharmacotherapy, bariatric surgery and the biology of regain
KFP 1 (10 marks)
A 48-year-old man with BMI 33 and prediabetes (HbA1c 6.0%) attends for review. He has tried multiple commercial diets with temporary success followed by regain. He asks whether there is 'anything that actually works'. [1]
- What does the DPP tell you about intensive lifestyle intervention for prediabetes? Quantify the results. (5) [1]
- What weight-loss target would you set and why? (3) [1]
- Would you add metformin? Justify. (2) [1]
Model answers
- The DPP randomised 3234 adults with prediabetes to intensive lifestyle intervention (goal: ≥7% weight loss and ≥150 min/week activity), metformin 850 mg BD or placebo over mean 2.8 years follow-up. Lifestyle reduced incident T2DM by 58% (95% CI 48–66%) versus placebo; metformin reduced it by 31%. NNT was 6.9 for lifestyle over three years — this is powerful prevention medicine. [1]
- Set 5–10% body-weight loss as the initial target. The DPP used a 7% goal; this magnitude of loss delivers clinically meaningful improvements in glycaemia, blood pressure and lipids without requiring normalisation of BMI. More is better but not required for clinical impact. [1]
- Yes, consider metformin 850 mg twice daily — it reduced incidence by 31% in DPP (NNT 13.9) and may suit a patient who cannot commit to intensive lifestyle change immediately. Lifestyle was significantly more effective than metformin but both beat placebo. [1]
References6ShowHide
- [1]Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 2002.PMID 11832527
- [4]Flegal KM, Kit BK, Orpana H, Graubard BI Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA, 2013.PMID 23280227
- [5]Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med, 2013.PMID 23796131
- [6]Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med, 2014.PMID 24679060
- [7]Fothergill E, Guo J, Howard L, Kerns JC, Knuth ND, et al. Persistent metabolic adaptation 6 years after 'The Biggest Loser' competition. Obesity (Silver Spring), 2016.PMID 27136388
- [8]Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med, 2017.PMID 28199805